Introduction
Immune checkpoint inhibitors (ICIs) are designed to restore a patient's antitumor immune response, which has been attenuated during the process of tumor development. Antigenpresenting cells normally express programmed death ligand 1 (PD-L1) that, when bound by PD-1 on T cells, signal an exhausted active immune response. In cancers that express PD-L1 on tumor cells, PD-1 receptor expressed on T cells, B cells, and natural killer cells of an activated immune system, and the interaction of PD-1 and PD-L1 characterizes an adaptive and immune-evasive response by the tumor. This immuneevasive interaction can be reversed by addition of ICIs that inhibit either molecule. 1 Recently, agents that modulate the tumor immune response have provided durable clinical benefit to patients with late-stage or recurrent disease. Nivolumab (Opdivo) has received Food and Drug Administration (FDA) approval for the treatment of squamous and nonsquamous metastatic non-small-cell lung cancer (NSCLC) and metastatic renal cell carcinoma with progression on or after chemotherapy. 2 Nivolumab is a human IgG4 antibody that blocks programmed death 1 (PD-1) receptor and potentiates activation of T cells. 3 Nivolumab therapy demonstrated improved tumor-related outcomes in multiple types of cancer. 4 Pembrolizumab (Keytruda), another PD-1 inhibitor, received FDA approval to treat advanced (metastatic) NSCLC whose disease has progressed after other treatments and with tumors that have 50% PD-L1 expression. 5 Programmed death ligand 1 inhibition facilitates activation of potentially autoreactive T cells, leading to inflammatory adverse events across a range of tissues. Patients with a history of autoimmune diseases were excluded from clinical trials of PD-1 inhibitors. 6 Exclusions included multiple sclerosis, autoimmune neuropathy, Guillain-Barré syndrome, myasthenia gravis, systemic lupus erythematosus, connective tissue diseases, scleroderma, inflammatory bowel disease, Crohn disease, ulcerative colitis, and hepatitis. Patients with rheumatoid arthritis, Sjögren syndrome, and psoriasis were included if disease was well-controlled. Although these therapies hold great promise, ICIs can trigger a variety of immune-related adverse Cancer Informatics events (irAEs). These include dermatologic, gastrointestinal, hepatic, endocrine, and other inflammatory conditions, and they are believed to result from general immune response enhancement. 7 Khan et al 8 have shown a relatively high rate of autoimmune diseases, approximately 14%, among patients with lung cancer, and these patients were more likely to be older women. The objective of this study was to confirm findings of Khan and colleagues in a more diverse cohort and identify whether patients with cancer with autoimmune disease exhibit different baseline characteristics and comorbidities.
Materials and Methods
We identified lung patients with and renal cancer using Truven Health MarketScan Commercial Claims and Medicare Supplemental Database. The MarketScan database includes approximately 40 million individuals from more than 160 large employers and health plans across the United States and includes health care claims with diagnosis and procedure codes for medical encounters and all prescription medication fills. These data are de-identified in compliance with the Health Insurance Portability and Accountability Act regulations, and the University of Kentucky Institutional Review Board approved the use of the database for this study.
Adults, 18 years and older, diagnosed with cancer between January 1, 2010 and November 31, 2013 were identified. At least 2 inpatient or outpatient diagnoses separated by at least 14 days were required, and the date of the first qualifying diagnosis of cancer was defined as the index date. We directed our analyses to only lung and renal cancer due to the initial approvals of the ICI, nivolumab. Nivolumab received approval for the treatment of metastatic NSCLC on March 4, 2015 and for metastatic renal cell carcinoma on November 23, 2015. Patients were required to have at least 12 months of preindex and a minimum of 1-month postindex continuous enrollment in the database. We assessed patients for diagnosis of autoimmune diseases prior to or after diagnosis of cancer using International Classification of Diseases, Ninth Revision codes for 41 autoimmune diseases. It is necessary to assess autoimmune disease before and after diagnosis because newly diagnosed autoimmune conditions would still have bearing on therapeutic decision-making practices. Prevalence was determined by the presence of 2 or more claims to autoimmune diseases separated by at least 30 days. Baseline characteristics and Elixhauser and Charlson comorbidity indexes of patients with and without autoimmune diseases were compared. These indexes include 17 and 31 categories of comorbid conditions, respectively, and have been widely used for risk adjustment with health outcomes data. 9,10 Two-sample t test and χ 2 tests were conducted to assess significant differences between groups. Bonferroni correction was applied due to multiple comparisons.
Results and Discussion
We identified 53 783 patients with lung cancer and 27 349 patients with renal cancer of whom 13 156 (24.5%) and 8217 (30.1%) also had an autoimmune disease, respectively. Hypothyroidism (55.8%, 56.7%), rheumatoid arthritis (20.2%, 18.1%), and type 1 diabetes mellitus (11.5%, 14.5%) were the most common for patients with both lung and renal cancers, respectively (Table 1) . Baseline characteristics and comorbidities are listed in Table 2 . Patients with cancer with autoimmune disease were more likely to be women, older, and had higher prevalence of comorbidities than patients with cancer without autoimmune disease (Table 2) .
More than a quarter of patients diagnosed with lung and renal cancer were found to have a comorbid autoimmune condition. When considering that immune checkpoint inhibition is only approved in late stages of cancer, it is not clear whether the benefits of pursuing treatment in patients with autoimmune disease outweigh the risk of inducing worse irAEs. Several case reports have been published showing that while discontinuation of the ICI results in resolution of the irAE, long courses of medications specific to the autoimmune reaction may be needed to mitigate the effects of ICI therapy. [11] [12] [13] In a large systematic review of 251 cases involving anti-CTLA-4 and anti-PD-1 agents, approximately 52% of treated patients discontinued ICI therapy due to the irAEs. 11 Less than 10% required no treatment for the irAE, whereas the remainder was treated with corticosteroids, infliximab (an antitumor necrosis factor agent), or disease-modifying antirheumatic drugs. Death due to the irAEs occurred in 4.7% of patients. Cutaneous autoimmune reactions are commonly associated with ICI therapy, but a case report on 2 patients with metastatic melanoma illustrated that irAEs may not appear until long after initiation of therapy. 13 An autopsy study presented an elderly patient with melanoma exhibiting a systemic inflammatory response that affected multiple organ sites ultimately resulting in the death of the patient. 14 
Limitations
This study is subject to the limitations of all claims-based studies. 15, 16 Notably, claims data lack detailed information on laboratory values or information on tumor staging, which may have influenced the outcomes of this study. This study was limited to a 1-year follow-up due to the availability of data and the heterogeneity and variation of time confounded with longer follow-up. This study is strengthened by a large sample size and the inclusion of both commercial and Medicare claims.
Conclusions
The exclusion of patients with autoimmune conditions from the approval studies of nivolumab and pembrolizumab resulted in a lack of clinical guidance for a large population of patients that oncologists must decide whether to treat or not. In latestage treatment of these cancers, the potential durable response associated with ICIs will need to be weighed against the worsening of the patient's autoimmune condition, a decision for which clinical trials have not provided a concrete answer. Future evaluation of real-world treatment patterns will be needed to assess ICI usage and response in patients with autoimmune conditions. Abbreviations: CHF, congestive heart failure; CHD, coronary heart disease; HIV, human immunodeficiency virus.
